Oxabact: Phase I/II started

OxThera began the double-blind, placebo-controlled, European Phase I/II OC5-DB-01 trial to evaluate twice-daily oral Oxabact in 24 patients with primary hyperoxaluria. Oxabact has Orphan Drug designat...